Last reviewed · How we verify
NanoPac®
At a glance
| Generic name | NanoPac® |
|---|---|
| Also known as | Paclitaxel |
| Sponsor | NanOlogy, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of NanoPac Intratumoral Injection in Lung Cancer (PHASE2)
- Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms (PHASE2)
- Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer (PHASE2)
- Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NanoPac® CI brief — competitive landscape report
- NanoPac® updates RSS · CI watch RSS
- NanOlogy, LLC portfolio CI